$ANEB

Anebulo Pharmaceuticals, Inc.

CIK:0001815974|SEC Filings

Condensed Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2025	Dec. 31, 2024
Income Statement [Abstract]
Research and development	$ 1,164,737	$ 1,220,535	$ 1,974,728	$ 2,535,394
General and administrative	1,455,173	1,367,616	2,905,442	2,464,881
Total operating expenses	2,619,910	2,588,151	4,880,170	5,000,275
Loss from operations	(2,619,910)	(2,588,151)	(4,880,170)	(5,000,275)
Other (income) expenses:
Interest expense	17,439	59,696	34,878	119,393
Interest income	(85,410)	(7,067)	(195,026)	(33,073)
Grant income	(552,576)	(177,703)	(562,401)	(423,065)
Other	34	(47)	130	236
Other income, net	(620,513)	(125,121)	(722,419)	(336,509)
Net loss	$ (1,999,397)	$ (2,463,030)	$ (4,157,751)	$ (4,663,766)
Weighted average common shares outstanding, basic	41,084,731	27,415,430	41,084,731	26,674,324
Weighted average common shares outstanding, diluted	41,084,731	27,415,430	41,084,731	26,674,324
Net loss per share, basic	$ (0.05)	$ (0.09)	$ (0.10)	$ (0.17)
Net loss per share, diluted	$ (0.05)	$ (0.09)	$ (0.10)	$ (0.17)

Condensed Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2025	Dec. 31, 2024
Cash flows from operating activities:
Net loss	$ (1,999,397)	$ (2,463,030)	$ (4,157,751)	$ (4,663,766)
Adjustments to reconcile net loss to net cash used in operating activities
Stock-based compensation	198,530	564,333	436,174	851,253
Amortization of loan commitment fee			34,879	119,393
Changes in operating assets and liabilities:
Grant receivable			16,435	(30,756)
Prepaid expenses			86,026	47,524
Accounts payable			330,687	125,492
Accrued expenses			667,271	455,127
Net cash used in operating activities			(2,586,279)	(3,095,733)
Cash flows from financing activities:
Proceeds from issuance of common stock				15,000,000
Net cash provided by financing activities				15,000,000
Net (decrease) increase in cash			(2,586,279)	11,904,267
Cash, beginning of period			11,627,849	3,094,200
Cash, end of the period	$ 9,041,570	$ 14,998,467	9,041,570	14,998,467
Noncash investing and finance activities:
Offering costs included in accounts payable				$ 37,597

Condensed Balance Sheets - USD ($)	Dec. 31, 2025	Jun. 30, 2025
Current assets:
Cash and cash equivalents	$ 9,041,570	$ 11,627,849
Grant receivable	56,783	73,218
Prepaid expenses	175,413	261,439
Total current assets	9,273,766	11,962,506
Other assets:
Loan commitment fees	148,231	183,110
Total assets	9,421,997	12,145,616
Current liabilities:
Accounts payable	554,862	224,175
Accrued expenses	930,784	263,513
Total liabilities	1,485,646	487,688
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value; 2,000,000 shares authorized, no shares issued or outstanding at December 31, 2025 and June 30, 2025
Common stock, $0.001 par value; 75,000,000 shares authorized and 41,084,731 shares issued and outstanding at December 31, 2025 and June 30, 2025	41,086	41,086
Additional paid-in capital	85,941,523	85,505,349
Accumulated deficit	(78,046,258)	(73,888,507)
Total stockholders’ equity	7,936,351	11,657,928
Total liabilities and stockholders’ equity	$ 9,421,997	$ 12,145,616